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Abstract Calea zacatechichi Schltdl. (Asteraceae alt.
Compositae) is a Mexican plant commonly used in folk med-
icine to treat respiratory and gastrointestinal (GI) disorders.
The objective of this study is to characterize the effect of
C. zacatechichi extracts in mouse models mimicking the
symptoms of irritable bowel syndrome (IBS). Powdered
C. zacatechichi herb (leaves, stems, and flowers) was extract-
ed with methanol. Methanolic extract was filtered and evapo-
rated giving methanolic fraction. The residue was extracted
with dichloromethane (DCM). Methanolic and DCM
(200 mg/kg, per os) extracts were screened for their effect
on GI motility in several in vitro tests, and the antidiarrheal
and antinociceptive effects were assessed using mouse
models. The influence of the DCM extract on motoric param-
eters and exploratory behaviors was also assessed. Finally, the
composition ofC. zacatechichiDCM extract was qualitatively
analyzed using liquid chromatography-mass spectrometry
(LC-MS) method. C. zacatechichi DCM extract significantly
inhibited the contractility of mouse colon in vitro
(IC50 = 17 ± 2 μg/ml). Administration of the DCM extract
in vivo (200mg/kg, per os) significantly prolonged the time of
whole GI transit (46 ± 1 vs. 117 ± 27 min for control and
DCM-treated animals, respectively; P = 0.0023), inhibited
hypermotility, and reduced pain in mouse models mimicking
functional GI disorders. Our findings suggest that constituents
of the C. zacatechichi DCM extract exhibit antidiarrheal and
analgesic activity. The extract may thus become an attractive
material for isolation of compounds that may be used as a
supplementary treatment for pain and diarrhea associated with
IBS in the future.
Keywords Diarrhea . Abdominal pain . Gastrointestinal
motility
Introduction
Irritable bowel syndrome (IBS) is a functional gastrointestinal
(GI) disorder with an estimated prevalence of 10–20 %
(Fichna and Storr 2012). According to Thompson et al.
(2000), it accounts for about 3 % of all general practice and
up to 40 % of all GI referrals. Symptoms of IBS, which in-
clude abdominal pain, altered stool consistency and frequen-
cy, diarrhea, and/or constipation, are caused mainly by distur-
bances in intestinal motility and/or secretion. Although IBS is
not life-threatening, it is a heavy economic burden due to
increased work absenteeism and impaired quality of life of
its sufferers, as well as increased use of health care services
(Sandler et al. 2002; Fichna and Storr 2012). Current under-
standing of the pathogenesis of IBS is unsatisfactory due to
the lack of demonstrable pathological abnormalities and reli-
able biomarkers (Fichna and Storr 2012). There are several
hypotheses concerning the pathology of IBS. One of them,
which is based on the analyses of specimens obtained at en-
doscopy and in serological cytokine studies, shows IBS as a
localized low-grade inflammatory disorder with mast cells
(MC) playing a particularly important role (Mayer and
Collins 2002; Philpott et al. 2011; Fichna and Storr 2012).
An alternative hypothesis states that food allergy may play a
key role (Atkinson et al. 2004). Concurrently, the bi-
directional communication between the gut and the central
nervous system (CNS) often related to as the brain-gut axis
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(BGA) is thought to have a crucial role in IBS pathogenesis
(Fichna and Storr 2012).
At present, pharmacological therapy for IBS focuses on alle-
viation of its symptoms, such as diarrhea or abdominal pain, but
not on the removal of its cause, which is mostly unrecognized.
There are several conventional and complementary therapies, as
well as herbal remedies for IBS, which have been recently
summarized by Yoon et al. (2011) and Rahimi and Abdollahi
(2012). Calea zacatechichi Schltdl. (Asteraceae alt.
Compositae) is a Mexican plant also known as Dream Herb
or, according to the Indian word Bzacatechichi,^ Bitter Grass.
It is native to Mexico and Central America. C. zacatechichi has
been used for centuries by Chontal Indians for rituals aiming at
dream-based divination, what suggests CNS-mediated, halluci-
nogenic action (Wu et al. 2011). Moreover, some Indian tribes
such as Zoque Popoluca have been using C. zacatechichi as a
remedy for cough and asthma, as well as GI tract disorders, such
as stomachache and diarrhea (Leonti et al. 2003). To date, sev-
eral biologically active compounds were isolated from the plant.
Recently, Wu et al. (2011) reported presence of six
germacranolides, which were shown to have antileishmanial
activity. Bork et al. (1997) found that the ethanolic extract from
C. zacatechichi leaves contains biologically active sesquiterpene
lactones, which were shown in vitro to inhibit activation of
NF-κB, a transcriptional factor and one of the major mediators
of inflammatory pathways. Other compounds and their biolog-
ical actions such as calaxin, ciliarin, caleins A and B, caleicins I
and II, acactein, zexbrevin, and neurolenin B were all reported
earlier in papers ranging from 1970 to 1980 (Wu et al. 2011).
In our search for possible novel treatments for functional
GI disorders, we employed two different extracts from
C. zacatechichi and tested their effect on the GI motility
in vitro and in vivo, in physiological and pathophysiological
conditions. Since abdominal pain is one of the most common
symptoms of IBS, we also used animal models to evaluate the
antinociceptive effects of C. zacatechichi extracts. The possi-
ble CNS-related effects of the extracts were evaluated by mea-
surement of their effect on locomotor activity of mice. The
chemical composition of the most active extract was evaluated




Dried shredded herb of C. zacatechichi (leaves, stems, and
flowers) was purchased from the company Maya
Ethnobotanicals (Haarlem, Netherlands). The material origi-
nated fromMexico according to the provider declaration. The
authenticity of the purchased material was confirmed through
the macroscopic and microscopic assessment which was
car r ied out in compar i son to the au then t ica ted
C. zacatechichi material from Daniel Siebert, provided by
the School of Pharmacy, University of Mississippi. The bo-
tanical name conforms to the International Plant Names Index
(Id: 187,802-1; Version: 1.2.2.1.1.3).
Extracts preparation
Powdered C. zacatechichi herb (150 g) was extracted four
times with boiling water. The aqueous solution was filtered
and lyophilized (water fraction). This extraction was carried
out due to the fact that in ethnomedicine, C. zacatechichi is
employed against GI disorders in this form (Mayagoitia et al.
1986). However, in our preliminary studies, the aqueous ex-
tract did not exhibit any biological activity; thus, we did not
use it in subsequent experiments (data not shown). The plant
residue was dried in a dryer at 50 °C for 1 day and extracted
withmethanol. Methanolic extract was filtered and evaporated
giving solid fraction (methanolic fraction). The residue was
extracted with dichloromethane (DCM). The solution was
evaporated, and as a result, 1.5 g of solid extract was obtained.
Animals
Experimentally naive male C57BL/6N mice were obtained
from the Animal House of the University of Lodz, Poland.
All animals (7–8 weeks old) used in experiments weighed
22–30 g. Mice were housed at a constant temperature
(22 °C) and maintained under a 12-h light/dark cycle (lights
on 6:00 a.m.) in sawdust-lined plastic cages with access to
chow pellets and tap water ad libitum. All animal protocols
were in accordance with the European Communities Council
Directive of 24 November 1986 (86/609/EEC) and Polish
legislation acts concerning animal experimentation. The ex-
perimental protocol was approved by the Local Ethics
Committee at the Medical University of Lodz (#590/2012).
All efforts were made to minimize animal suffering and to
reduce the number of animals used. All experiments conduct-
ed in these study are based on the well-established methodol-
ogy which is routinely used in the authors’ laboratory (for
reference please see Zielinska et al. (2015), Fichna et al.
(2014a, b), Sałaga et al. (2014) and Fichna et al. (2014a, b))
and produce repetitive results. Hence, we did not use positive
controls in all experiments to validate the models. We used
loperamide as a positive control in the model of diarrhea for
the sake of comparison of its effect with the antidiarrheal
effect of the C. zacatechichi DCM extract.
In vitro experiments on isolated smooth muscle strips
Organ bath experiments were performed according to the
method described elsewhere (Sałaga et al. 2014). Briefly, mice
were sacrificed by cervical dislocation. Full-thickness
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segments (1 cm) of distal colon were removed and kept in ice-
cold oxygenated Krebs solution (NaCl 115mM, KCl 8.0 mM,
KH2PO4 2.0 mM, NaHCO3 25 mM, MgCl2 2.4 mM, CaCl2
1.3mM, and glucose 10mM). All experiments lasted less than
3 h, and each preparation was used for a single experiment
only. Each segment was mounted between two platinum elec-
trodes in organ baths containing Krebs (25 ml) equilibrated
with 95 % O2 and 5 % CO2 at 37 °C. One end of each prep-
aration was attached to the bottom of the organ bath using a
silk thread, while the other end was connected to a FT03 force
displacement transducer (Grass Technologies, West Warwick,
RI, USA). Tension (0.5 g) was applied, and the preparations
were allowed to equilibrate for 30 min. Changes in tension
were amplified by a P11T amplifier (Grass Technologies,
West Warwick, RI, USA) and recorded on a personal comput-
er using the POLYVIEW software (Polybytes Inc., Cedar
Rapids, IA, USA). Tissue strips were subjected to electrical
field stimulation (EFS) applied by a S88X stimulator (Grass
Technologies, EFS 8 Hz, 60 V, pulse duration 0.5 ms, train
duration 10 s). EFS of isolated smooth muscle strips caused
twitch contractions, which were virtually abolished by the
muscarinic receptor antagonist atropine (10−6 M) or the neural
blocker tetrodotoxin (10−6 M).
The contractile responses were characterized in the pres-
ence of increasing cumulat ive concentrat ions of
C. zacatechichi methanol and DCM extracts (both 10–4.6 to
10–1.6 mg/ml), with the contact time for each concentration of
10 min. Before the addition of drugs, the mean amplitude of
four successive twitch contractions was used as an internal
control. Changes in contractions were reported as the percent-
age of the internal control. In control experiments, the effect of
the vehicle was tested.
In vivo investigation of whole gastrointestinal transit
Whole gut transit test evaluates the time of passage of the
nonabsorbable colored marker (150 μl of glutinous liquid,
consisting of 5 % Evans blue and 5 % Arabic gum) through
the GI tract. Vehicle, C. zacatechichi methanol, or DCM ex-
tracts (200 mg/kg, p.o.) were injected 15 min before marker
administration. Immediately after the intragastric administra-
tion of the marker, mice were returned to individual cages,
which were placed on a white sheet in order to facilitate rec-
ognition of colored boluses. Time elapsed between intragastric
administration of the marker and the excretion of the first col-
ored fecal bolus was considered as whole gut transit time.
Colonic bead expulsion test
Distal colonic expulsion was measured as reported recently
(Sibaev et al. 2009). Briefly, animals were fasted overnight;
C. zacatechichi DCM extract (100, 200, and 300 mg/kg, p.o.)
or vehicle were administered p.o. (150 μL), and 15min later, a
prewarmed (37 °C) glass bead (2-mm diameter) was inserted
into the distal colon (2-cm depth) using a silicone pusher.
After insertion of the bead, mice were moved to individual
cages and the time to bead expulsion was measured. Mice that
did not expel the bead within 30 min were sacrificed to con-
firm the presence of the bead in the lumen of the colon.
Mouse model of castor oil-induced diarrhea
To induce diarrhea, animals (fasted for 12 h before experi-
ment) were gavaged with 200 μl of castor oil and then placed
into individual cages for observation. Clean paper was put
under each cage to improve the contrast. The time elapsed
between administration of castor oil and the appearance of
first symptoms of diarrhea (excretion of liquid feces) was
measured and compared between groups. Loperamide (LOP)
was used as a reference drug. C. zacatechichi DCM extract
(200 mg/kg, p.o.), LOP (1 mg/kg, intraperitoneal; i.p.), or
vehicle (p.o.) was administered 15 min prior to the gavage
of the castor oil. The methodology was described earlier by
Sałaga et al. (2014).
Behavioral pain responses
Behavioral responses to intracolonic (i.c.) administration of
mustard oil (MO, allyl isothiocyanate) were determined as
described previously (Laird et al 2001; Eijkelkamp et al.
2007). Briefly, Vaseline was applied to the perianal area to
exclude the stimulation of somatic areas and then 50 μl of
MO (1 % in 70 % ethanol) was injected i.c. under isoflurane
anesthesia. After 5 min of recovery, spontaneous behaviors
were recorded on a videotape for 20 min for later analysis
by an observer blinded to experimental conditions. Pain-
related behaviors including (1) licking of the abdomen, (2)
squashing of lower abdomen against the floor, (3) stretching
the abdomen, and (4) abdominal retractions were each count-
ed as 1.
C. zacatechichiDCM extract (200mg/kg, p.o.) was admin-
istered 15 min before the MO instillation. Five percent di-
methyl sulfoxide in saline was used as vehicle in control
experiments.
The writhing test was performed as described earlier (Laird
et al. 2001; Gach et al. 2010; Fichna et al. 2013). Fifteen
minutes after administration of vehicle or C. zacatechichi
DCM extract (200 mg/kg, p.o.), mice were injected i.p. with
acetic acid solution (10 ml/kg of 0.75 %, v/v in saline). After
the injection, mice were placed in individual cages for obser-
vation and the total number of writhes was counted 5 min
later, during three periods of 5 min each. The writhing re-
sponse, regarded as a nociceptive behavior, was characterized
by elongation of the body and the development of tension in
the abdominal muscles and hind paws.
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Measurement of locomotor activity
Locomotor activity was assessed according to the method de-
scribed by Cravezic et al. (2011). Briefly, measurement was
made automatically in a Digiscan actimeter (Omnitech
Electronics Inc., Columbus, OH, USA), which monitored hor-
izontal displacements and vertical movements. The animals
were placed individually in 20 × 20 × 30 cm compartments,
in a dimly illuminated and quiet room. The responses were
expressed as the number of crossed infrared beams by mouse
during four consecutive 15-min periods.
LC-MS analysis of C. zacatechichi DCM extract
A tandem mass spectrometer MicrOTOF-Q II from Bruker
Daltonik (Bremen, Germany) coupled with an LC-UV
Ultimate 3000 system (Dionex, a part of Thermo Fisher
Scientific) was used to obtain the electrospray ionization
time-of-flight mass spectra (LC-ESI-MS/MS-TOF). The fol-
lowing settings were used: electrospray ionization (ESI) in the
positive ion mode, dry gas (nitrogen) flow rate 8.0 l min−1, the
dry heater 180 °C, the capillary voltage 4500 V, and end plate
offset −500 V. MS data were recorded in the full scan mode
(from 50 to 3000 m/z). Data processing was carried out with
Compass 1.3 (Bruker Daltonik).
Chromatographic analysis was performed on a C18 analyt-
ical column (Hypersil GOLD, 150 mm × 2.1 mm; 3-μm par-
ticle size; Thermo Fisher Scientific,Waltham,MA, USA)with
a guard column (Hypersil GOLD, 10 mm × 2.1 mm; 3-μm
particle size; Thermo Fisher Scientific). The linear gradient
elution was performed using 0.1 % formic acid in solvent A
(water/acetonitrile, 9:1, v/v) and 0.1 % formic acid in solvent
B (methanol/acetonitrile, 9:1, v/v). An applied linear gradient
was as follows: initially 10 % B from 0 to 2 min, then linear
gradient to 90 % B at 7 min, constant 90 % B to 10 min, and
finally return to 10 % B and equilibration for 2 min. The flow
rate was 0.15 ml min−1, and the injection volume was 2 μl.
The analysis was carried out at 25 °C.
The identification of individual compounds was based on the
analysis of high resolution mass spectra. Time of flight analyzer
enables a very accurate mass detection, resulting in the assign-
ment to the most probable molecular formula. Suggested mo-
lecular formulas were accepted when the mass error was below
5 ppm. The identification was further enhanced by the analysis
of the isotopic pattern of the compounds. If possible, obtained
MS/MS spectra were additionally compared with spectra of
identified compounds in the METLIN: Metabolite and
Tandem MS Database (http://metlin.scripps.edu).
Drugs
All drugs and reagents, unless otherwise stated, were pur-
chased from Sigma-Aldrich (Poznan, Poland). Loperamide
was purchased from Tocris Bioscience (Bristol, UK). In the
in vitro experiments (isolated smooth muscle strips), all drugs
were dissolved in dimethyl sulfoxide. In the in vivo tests,
drugs were dissolved in 5 % dimethyl sulfoxide in saline,
which was used as vehicle in control experiments. The vehi-
cles in the used concentrations had no effects on the observed
parameters.
Statistics
In the in vitro experiments, n denotes the number of individual
tissues from at least three different animals. Statistical analy-
ses were performed using PRISM 5.0 (GraphPad Software
Inc., La Jolla, CA, USA). The data are expressed as
means ± SEM. Student’s t test was used to compare single
treatment means with control means. Analysis of variance
(ANOVA) followed by Newman-Keuls post hoc test was used
for analysis of multiple treatment means. P values ≤0.05 were
considered statistically significant.
Results
Inhibitory activity of C. zacatechichi on ex vivo smooth
muscle contractility
We first investigated the effect of C. zacatechichi methanol
and DCM extracts on isolated mouse colon contractility. Both
extracts (10–4.6–10–1.6 mg/ml) inhibited the EFS-induced
twi tch contract ion to a comparable extent , in a
concentra t ion-dependent manner ( IC50 va lue of
16.66 ± 1.54 μg/ml and 18.48 ± 1.22 μg/ml for DCM and
methanol extracts, respectively, Fig. 1a, b). The maxi-
mum inhibitory effect of both compounds was approxi-
mately 50 %.
In vivo inhibitory activity of C. zacatechichi in whole
gastrointestinal transit test
As shown in Fig. 2, only DCM extract, administered p.o.,
produced a potent, inhibitory effect on whole GI motility.
Therefore, the DCM extract was used in subsequent
experiments.
In vivo inhibitory activity of C. zacatechichi colonic bead
expulsion test
C. zacatechichi DCM extract produced a significant dose-
dependent inhibitory effect on colonic expulsion 15 min after
administration (Fig. 3a). The effect was relatively short last-
ing, as it was not observed 45 min after administration of the
extract (Fig. 3b).
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This experiment showed that the oral dose of 200 mg/kg is
sufficient to elicit significant effect on the GI tract motility
in vivo. Hence, we proceeded with this dose in all subsequent
in vivo experiments.
Antidiarrheal activity of C. zacatechichi DCM extract
in mouse
To investigate the antidiarrheal activity of C. zacatechichi DCM
extract, we used a mouse model of castor oil-induced diarrhea.
Intragastric administration of castor oil caused an accumulation
of water and electrolytes in the mouse intestine, what resulted in
an acute diarrhea in control animals (Fig. 4). C. zacatechichi
DCM extract (200 mg/kg p.o.) significantly delayed the emer-
gence of liquid feces, and its effect was more marked than that
obtained with the antidiarrheal drug loperamide (1 mg/kg, i.p.);
more specifically, the extract prevented diarrhea in nearly all
experimental animals until the cutoff time (Fig. 4).
Antinociceptive activity of C. zacatechichi DCM extract
in mouse models of abdominal pain
In order to assess the antinociceptive activity of
C. zacatechichi DCM extract, two different mouse models
of abdominal pain were used. In the behavioral model elicited
Fig. 1 Effect of C. zacatechichi DCM (a) and methanol (b)
extracts (10–4.6–10–1.6 mg/ml) on EFS-stimulated longitudinal smooth
muscle contractions in mouse colon (8 Hz, 60 V, pulse duration 0.5 ms,
train duration 10 s). Data represent mean ± SEM for n = 4–7 experiments.
*P < 0.05, **P < 0.01, ***P < 0.001 as compared to control
Fig. 2 Effect of C. zacatechichi DCM and methanol extracts (both
200 mg/kg, p.o.) on whole GI transit time. Data represent mean ± SEM
of n = 6–10 animals. **P < 0.01, as compared with the control group
Fig. 3 Effect of C. zacatechichi DCM extract on lower GI tract motility
in the colonic bead expulsion test. The dose-effect relationship of 100,
200, and 300 mg/kg, p.o. on the colonic bead expulsion time (a). Time
course of changes of bead expulsion time after administration of
C. zacatechichi DCM extract at the dose of 200 mg/kg, p.o. (b). Two
control groups (15 and 45 min after administration of the DCM extract)
were used to take into account the adaptive changes in the colonic smooth
muscle that typically occur after the second insertion of the bead. Data
represent mean ± SEM of n = 6–8 mice for each experimental group.
*P < 0.05, **P < 0.01, ***P < 0.001, as compared with control
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by the i.c. injection of MO, the p.o. administration of
C. zacatechichi DCM extract (200 mg/kg) resulted in a sig-
nificant antinociceptive effect (Fig. 5a). Similarly, the p.o.
administration of C. zacatechichi DCM extract at the dose of
200 mg/kg resulted in a significant reduction of the number of
writhes (Fig. 5b).
C. zacatechichi DCM extract does not affect motor
functions in mice
The influence of the p.o. administration of C. zacatechichi
DCM extract on mouse locomotor activity was measured over
six consecutive periods of 10 min each. The extract adminis-
tered at a dose of 200 mg/kg did not modify total locomotor
activity in any of the time periods of the test (Fig. 6).
The LC-MS analysis of C. zacatechichi DCM extract
Table 1 reports the measured accurate ion mass (M+H)+ or
(M+Na)+ of the analyzed compounds and the corresponding
mos t p robab l e mo l e cu l a r f o rmu l a . The l i qu i d
chromatography-mass spectrometry (LC-MS) analysis of the
extract showed the presence of nine constituents, which are
coumarin derivatives (1, 2, 3), flavone derivative (4), and
germacranolides (5, 6, 7, 8, 9; Table 1). Comparison of the
mass spectra of the constituents with the METLIN library or
published papers (Chouchi and Barth 1994; Wu et al. 2011;
Liu et al. 2012) resulted in the following list of compounds: 7-
methoxy-2H-chromen-2-one (1); 5,7-dimethoxy-2H-chro-
men-2-one (2); 6,7,8-trimethoxy-2H-chromen-2-one (3);
acacetin (4); calealactones: C (6), D (9), and E (5); 8β-
angeloxy-9α-acetyloxycalyculatolide (7); and calein A (8).
Discussion
In this study, we characterized the effect of C. zacatechichi
DCM extract on motility and abdominal pain with in vitro and
in vivo tests. We found that the extract is a strong regulator of
intestinal motility in both physiological and pathophysiologi-
cal conditions as well as pain signaling. The latter effect is
particularly important since abdominal pain is one of the ma-
jor symptoms of all types of IBS.
Plant extracts are a well-known source of biologically ac-
tive compounds, which may be used for the treatment of var-
ious conditions, e.g., IBS, in which classical pharmacological
therapies do not provide sufficient relief. Depending on the
main symptom, three types of IBS may be distinguished:
constipation-predominant (IBS-C), diarrhea-predominant
(IBS-D), and altering bowel habits (IBS-A). The major goals
of anti-IBS therapies are control of colonic motility and ab-
dominal pain. Currently available pharmacological treatments
are mainly targeted at reduction of symptoms but not complete
healing. In addition, some patients may have coexisting con-
ditions that contribute to the severity of IBS symptoms, re-
quiring further consideration when choosing treatment op-
tions (Yoon et al. 2011).
To date, various classes of drugs have been tested as po-
tential anti-IBS therapy, for instance 5-HT3 antagonists and
bile acid-binding agents (for IBS-D), 5-HT4 agonists, and
Fig. 4 Antidiarrheal activity of C. zacatechichi DCM extract. The effect
of C. zacatechichi DCM extract (200 mg/kg, p.o.) and LOP (1 mg/kg,
i.p.) on the delay of the emergence of castor oil-induced diarrhea. Data
represent mean ± SEM of n = 6–8 mice for each experimental group.
*P < 0.05, ***P < 0.001, as compared to castor oil-treated/control
animals
Fig. 5 Antinociceptive activity of C. zacatechichi DCM extract. a The
effect ofC. zacatechichiDCM extract (200 mg/kg, p.o.) on the number of
pain-related behaviors evoked by i.c. administration of mustard oil (MO).
b The effect of p.o. administered C. zacatechichi DCM extract
(200 mg/kg) on the number of writhes. Data represent mean ± SEM of
n = 6–8mice per group. *P < 0.05, **P < 0.01, as compared toMO/acetic
acid-treated animals
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chloride channel activators (for IBS-C) (Manabe et al. 2010).
Moreover, peripheral kappa-opioid receptor agonists such as
asimadoline or salvinorin A derivatives have been proposed as
visceral analgesics in IBS-D (Manabe al. 2010; Sałaga et al.
2014). However, many of these drugs do not improve suffi-
ciently disease symptoms or may cause side effects which
force patients to seek nonprescribed pharmacological regi-
mens falling within complementary and alternative medicine
(CAM) therapies. A study by Kong et al. (2005) has shown
that the incidence of CAM use is 50.9 % for IBS patients;
moreover, about 50 % of CAM users perceived improvement
of symptoms (Yoon et al. 2011).
Several studies concerning the use of single herbal medi-
cines in IBS have recently been reported. For instance, it has
been shown that 4-week treatment with enteric-coated pepper-
mint capsules twice daily or before meals significantly re-
duces IBS symptoms and increases quality of life (QOL)
(Cappello et al. 2007; Merat et al. 2010). Moreover, Bundy
et al. (2004a and 2004b) have reported the anti-IBS activity of
turmeric and artichoke extracts, which significantly improved
the IBS symptoms and QOL. Finally, multiple herbal prepa-
rations such as Iberogast, Padma Lax, and Tong Xie Yao Fang
have been tested for anti-IBS activity and are described in
detail by Yoon et al. (2011). These data indicate that natural
product-derived preparations constitute an important branch
of anti-IBS medications.
Here, for the first time, we report the actions of
C. zacatechichi DCM extract, which may be employed in
the treatment of IBS. We found that the extract inhibited mo-
tility in the lower GI tract in a dose-dependent manner. This is
particularly important in the treatment of IBS-D, where
disrupted colonic motility enhances the frequency of defeca-
tion. Moreover, in pathophysiological conditions,
C. zacatechichi DCM extract exhibited outstanding antidiar-
rheal activity, even more potent than that of a well-known
drug loperamide, and was active after oral administration.
Altered intestinal motility is often accompanied with abdom-
inal pain, which is one of the most common symptoms that
Fig. 6 Effect of C. zacatechichi DCM extract (200 mg/kg, p.o.) on total
locomotor activity. Bars on the left side of the graph represent total
number of counts in subsequent 15-min time period. Bars on the right
side of the graph show cumulative values of a total number of counts in
the time periods indicated on the OX axis of the graph. Depicted are
means ± SEM of n = 6–8 mice per group
Table 1 Chemical
characterization of the
C. zacatechichi DCM extract
No. a[M + H]+
b[M + Na]+
(m/z)
Empirical formula Name Reference
1 a177.056 C10H8O3 7-Methoxy-2H-chromen-2-one Kielbus et al. 2013
2 a207.066 C11H10O4 5,7-Dimethoxy-2H-chromen-2-one Chouchi and
Barth 1994
3 a237.077 C12H12O5 6,7,8-Trimethoxy-2H-chromen-2-one Galabov et al. 1996
4 a285.077 C16H12O5 Acacetin Liu et al. 2012
5 a363.180 C20H26O6 Calealactone E Wu et al. 2011
6 a407.170 C21H26O8 Calealactone C Wu et al. 2011
7 a419.170 C22H26O8 8β-angeloxy-9α-acetyloxycalyculatolide Wu et al. 2011
8 a421.185 C22H28O8 Calein A Wu et al. 2011
9 b443.170 C22H28O8 Calealactone D (sodium adduct) Wu et al. 2011
The superscript letters before the values correspond to the superscript letters in the header
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lead IBS patients to gastroenterology clinics. Consequently, in
this study, we showed that C. zacatechichi DCM extract alle-
viates abdominal pain in two well-established animal models
after oral administration. These features make the extract a
promising candidate for a source of anti-IBS compounds.
Chemical analysis of the C. zacatechichi DCM extract re-
sulted in the identification of several germacranolides, which
were previously detected by Wu et al. (2011). These com-
pounds were shown to have anti leishmanial and
antimicrobial activities in vitro. Moreover, Umemura et al.
(2008) demonstrated that germacranolides such as
calealactone A activate the nuclear factor E2-related factor 2
(Nrf2)/antioxidant response element (ARE) pathway and in-
duce the phase II detoxification/antioxidant enzymes upon
oxidative stress, thereby resulting in an increased resistance
to oxidative damage. The next group of compounds which we
identified in DCM extract of C. zacatechichi was cou-
marin derivatives. Coumarin is a well-known anticoagu-
lant, and to date, it was not shown to exhibit antidiar-
rheal activity. On the other hand, recent data suggest
that coumarin as well as its derivatives produce
antinociceptive effect in the writhing test in mice after
oral administration (Park et al. 2013; Alipour et al.
2014). This experimental data suggest the contribution
of coumarin derivatives in inhibition of abdominal pain
in our study. We also detected the presence of acacetin
in our extract. However, we did not find any literature
data concerning the effect of this compound on the GI
tract.
As known from occasional users as well as one scientific
report, C. zacatechichimay affect the CNS. At the doses used
by humans, organic extracts of the plant produce behavioral
signs of somnolence and induce light sleep in cats
(Mayagoitia et al. 1986). Large doses may produce other side
effects, such as salivation, ataxia, retching, and occasional
vomiting. A controlled nap sleep study showed that
C. zacatechichi extracts increased the number of superficial
stages of sleep and the number of spontaneous awakenings
(Mayagoitia et al. 1986). Moreover, Mayagoitia et al. (1986)
demonstrated that methanol extract elicits larger psychophar-
macologic effects than hexane extract, suggesting that active
compounds might be found in the polar rather than nonpolar
fraction. Taking that into consideration, one of our most
prominent goals was to evaluate whether nonpolar
C. zacatechichi DCM extract produces CNS-related ef-
fects. We found that the extract did not affect locomotor
activity of animals when administered at the doses
which produce potent antidiarrheal and antinociceptive
effects in the GI tract. We thus suggest that psychoac-
tive constituents of C. zacatechichi are not present in
DCM extract, what guarantees potential safe use of the
preparation in patients. However, further studies are
warranted to confirm this observation.
Conclusion
C. zacatechichi DCM extract exhibits potent action in the GI
tract and produces a significant antidiarrheal and
antinociceptive effect in mouse models mimicking IBS-D.
Moreover, our data suggest that the preparation does not elicit
behavioral changes associated with CNS-related effects of
C. zacatechichi. Furthermore, the extract is active after oral
administration. Further chemical analyses of C. zacatechichi
are thus urgently needed in order to find all its active constit-
uents, which may open up new opportunities for the discovery
of novel therapeutics for functional GI diseases, including
IBS-D.
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